<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01542411</url>
  </required_header>
  <id_info>
    <org_study_id>2362</org_study_id>
    <nct_id>NCT01542411</nct_id>
  </id_info>
  <brief_title>Effectiveness of Aspirin in Compare With Heparin Plus Aspirin in Recurrent Pregnancy Loss Treatment</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yazd Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yazd Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluated the effect of anticoagulant treatment on the live-birth rate in women
      with a history of at least two continuous unexplained miscarriages or thrombophilia. It also
      compared two methods of treatment with aspirin and aspirin plus heparin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">520</enrollment>
  <condition>Recurrent Pregnancy Loss</condition>
  <arm_group>
    <arm_group_label>recurrent pregnancy loss</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>thrombophilia, aspirin</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>heparin</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        This project evaluated 520 women with unexplained recurrent miscarriage for four years.
        They had referred to recurrent abortion clinic of Yazd Reproductive sciences institute.
        Women with unexplained recurrent miscarriage included in this study
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  unexplained recurrent miscarriage,

          -  women had previous venous or arterial thromboembolism or who were heterozygous or
             homozygous for mutations for FV Leiden G1691A, prothrombin gene G20210A (FII G20210A),
             and methyltetrahydrofolate reductase C677T (MTHFR C677T)

        Exclusion Criteria:

          -  abnormal karyotypes of both partners,

          -  uterine and cervical anatomical disorders on pelvic ultrasonography or hysteroscopy,

          -  abnormal ovaries and abnormal endocrine tests.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tahere Jahaninejad, MSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yazd Shahid Sadoughi Medical Sciences University and Health Services, Yazd, Iran</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research and Clinical Centre for Infertility</name>
      <address>
        <city>Yazd</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2012</study_first_submitted>
  <study_first_submitted_qc>March 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2012</study_first_posted>
  <last_update_submitted>March 1, 2012</last_update_submitted>
  <last_update_submitted_qc>March 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Spontaneous</mesh_term>
    <mesh_term>Fetal Death</mesh_term>
    <mesh_term>Abortion, Habitual</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

